SVB Securities analyst Marc Goodman maintained a Buy rating on ACADIA Pharmaceuticals (ACAD - Research Report) today and set a price target of $21.00. The company's shares closed yesterday at $16.62.According to TipRanks, Goodman is a 3-star analyst with an average return of 2.5% and a 47.73% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Avadel Pharmaceuticals, Jazz Pharmaceuticals, and SAGE Therapeutics.In addition to SVB Securities, ACADIA Pharmaceuticals also received a Buy from JMP Securities's Jason Butler in a report issued today. However, on the same day, Citigroup maintained a Hold rating on ACADIA Pharmaceuticals (NASDAQ: ACAD).
https://www.tipranks.com/news/blurbs/svb-securities-sticks-to-their-buy-rating-for-acadia-pharmaceuticals-acad?utm_source=advfn.com&utm_medium=referral
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Acadia Pharmaceuticals Charts.
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Acadia Pharmaceuticals Charts.